BPC-157 Research: What Published Studies Have Investigated

What is BPC-157?

What is BPC-157? It is a synthetic 15-amino-acid peptide — a pentadecapeptide, from the Greek penta-deca for fifteen — corresponding to a partial sequence, or fragment, of a larger protein that was identified in gastric juice. The molecule was first characterised in the research literature in the early 1990s, and it is that gastric-protein origin that gives it the “body protection compound” name from which the BPC abbreviation derives.

The important distinction to hold from the outset is that BPC-157 is a laboratory synthetic. It is manufactured to a defined sequence rather than extracted from tissue, and in research catalogues it is supplied as a lyophilized (freeze-dried) powder for bench work. Everything in this definition is a molecule fact — sequence, origin, form — and says nothing about use in any organism.

Reference data

The molecule facts below are drawn from the public chemical record (PubChem CID 9941957) and standard catalogue data. They describe identity and physical form only.

BPC-157 is a short, single-chain peptide, which places it at the small end of the peptide-size range and is part of why it is comparatively straightforward to synthesise and characterise. The literature describes it as relatively stable for a peptide of its class — a practical property that, with its small size, is a large part of why it became a research-catalogue staple. Identity and measured purity for any given batch are documented on that batch’s Certificate of Analysis rather than assumed. These are molecule and handling facts only; none implies a use, a benefit, or a route of administration.

Mechanisms researchers have examined

A defining feature of the BPC-157 literature is that it does not converge on a single receptor. Instead, studies describe the peptide as pleiotropic — acting through, or being associated with, several distinct signalling pathways rather than one defined target. That is unusual enough that “no single receptor” is itself one of the most-repeated observations about the molecule. Among the mechanisms studies have investigated:

• Studies investigated VEGFR2-mediated angiogenesis — Hsieh et al. (2017, J Mol Med, PMID 27847966) associated BPC-157 with VEGFR2 activation and an Akt–eNOS signalling axis in model systems.
• Studies investigated growth-hormone-receptor upregulation in tendon fibroblasts (Chang et al., 2014, Molecules, PMID 25415472).
• Studies investigated tendon-fibroblast outgrowth, survival and migration in culture (Chang et al., 2011, J Appl Physiol, PMID 21030672).
• Studies investigated modulation of the nitric-oxide (NO) system (Sikiric et al., 2014, Curr Pharm Des, PMID 23755725).
• Studies investigated cytoprotection and cytokine / stress-response modulation across organ systems (Sikiric et al., 2020, Gut Liver, PMID 31158953).

Because these are described as multiple, overlapping pathways rather than one defined receptor, the literature frames BPC-157 as pleiotropic. Each bullet above names a research direction examined in model systems, not an outcome, a benefit, or an effect a reader should expect.

Research models and evidence status

Most BPC-157 research is preclinical, meaning it is conducted in cell cultures and animal models rather than in people. The reported model systems cluster into a few areas: tendon and ligament models, gut-mucosal models (consistent with the peptide’s gastric-protein origin, reviewed in Sikiric et al., 2011, PMID 21548867), broader musculoskeletal models, and a smaller neurological literature. These are the settings in which the mechanisms above were investigated.

A 2025 systematic review in the orthopaedic sports-medicine literature (Vasireddi et al., HSS Journal, PMID 40756949) surveyed this body of work and reported that 35 of 36 included studies were preclinical, with the human-relevant data at the lowest evidence levels. A Phase 2 hamstring-injury trial is registered (ClinicalTrials.gov NCT07437547) but has no published results. The caveat that should accompany every honest summary, stated plainly: there is little human evidence. What is not established is any effect of the material in a person — the literature is a record of what was investigated in models, and anyone weighing it should read it in that light rather than as human data.

BPC-157 in the tissue-repair peptide group

In research catalogues, BPC-157 is usually grouped with other peptides studied in tissue-repair and recovery contexts, most often TB-500 (a synthetic fragment related to thymosin beta-4). The two are distinct molecules with separate literatures, and the only comparison this page makes is one of research focus — which questions each has been studied under — because the published work examines them independently.

Nothing here is combination, stacking or protocol guidance: the fact that two peptides appear in the same research area is not a suggestion to use them together, and we make no such suggestion. Read the sibling TB-500 / thymosin β4 research deep-dive, and the blend explainer Wolverine research blend. More context on the tissue-repair group is on the research overview.

How to verify this compound yourself

For a small peptide, identity and purity are established by two orthogonal analytical methods, both reported on a per-batch Certificate of Analysis:

• HPLC purity — reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and reports purity as a percentage.
• Mass-spec identity — mass spectrometry confirms the measured mass against the expected molecular weight (≈ 1419.5 Da).
• Endotoxin / sterility — where tested, separate quality attributes reported independently of chemical purity.

See how to read a COA for what each certificate line means and how to verify peptide purity for how HPLC and mass spec fit together. Check the exact batch on the self-serve verify tool.

Research-grade sourcing and verification

Cellworks supplies BPC-157 for research use only, with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation. Because the mechanism literature is only as meaningful as the identity of the material used, the batch a researcher receives can be checked directly: enter the lot number on the self-serve verify tool to pull that batch’s COA, and see our quality standards for how each lot is tested and documented.

Frequently asked questions

Literature cited

1. Sikiric P, Seiwerth S, Rucman R, et al. “Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.” Curr Pharm Des. 2011;17(16):1612–1632. PMID 21548867. pubmed.ncbi.nlm.nih.gov/21548867.
2. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.” J Appl Physiol. 2011;110(3):774–780. PMID 21030672. pubmed.ncbi.nlm.nih.gov/21030672.
3. Chang CH, Tsai WC, Hsu YH, Pang JHS. “Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts.” Molecules. 2014;19(11):19066–19077. PMID 25415472. pubmed.ncbi.nlm.nih.gov/25415472.
4. Hsieh MJ, Liu HT, Wang CN, et al. “Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation.” J Mol Med (Berl). 2017;95(3):323–333. PMID 27847966. pubmed.ncbi.nlm.nih.gov/27847966.
5. Sikiric P, Seiwerth S, Rucman R, et al. “Stable gastric pentadecapeptide BPC 157–NO-system relation.” Curr Pharm Des. 2014;20(7):1126–1135. PMID 23755725. pubmed.ncbi.nlm.nih.gov/23755725.
6. Sikiric P, Rucman R, Turkovic B, et al. “Stable Gastric Pentadecapeptide BPC 157 … Progress, Achievements, and the Future.” Gut Liver. 2020;14(2):153–167. PMID 31158953. pubmed.ncbi.nlm.nih.gov/31158953.
7. Vasireddi N, Hahamyan H, Salata MJ, et al. “Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.” HSS J. 2025. PMID 40756949. pubmed.ncbi.nlm.nih.gov/40756949.
8. ClinicalTrials.gov. “BPC 157 for Acute Hamstring Muscle Strain Repair” (Phase 2). NCT07437547. clinicaltrials.gov/study/NCT07437547.
9. National Center for Biotechnology Information. “PubChem Compound Summary for CID 9941957, BPC 157.” pubchem.ncbi.nlm.nih.gov/compound/9941957 (formula, mass).